Scholar Rock Highlights Myostatin Research Progress at Goldman Sachs Healthcare Conference
Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha
Image: Seeking Alpha
At the Goldman Sachs 47th Annual Global Healthcare Conference, Scholar Rock's CEO David Hallal discussed the company's advancements in myostatin biology, particularly the successful Phase III trial of apitegromab for spinal muscular atrophy (SMA), and outlined future developments over the next 12 to 18 months.
- 01Scholar Rock is a leader in myostatin biology, a field it has focused on since 1997.
- 02The company's lead asset, apitegromab, has shown statistically significant benefits in motor function for SMA patients.
- 03Scholar Rock's unique technology platform is the first to advance a myostatin inhibition program through late-stage development successfully.
- 04The company aims to file for regulatory approval based on positive trial results within the next 12 to 18 months.
- 05David Hallal emphasized the importance of their clinical findings in improving the lives of children and adults with SMA.
Advertisement
In-Article Ad
At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026, David Hallal, CEO and Chairman of Scholar Rock Holding Corporation (SRRK), provided insights into the company's pioneering work in myostatin biology. Scholar Rock, based in Cambridge, is recognized as a leader in this field, having developed the first and only myostatin inhibition program that has progressed through mid- and late-stage clinical trials. Hallal highlighted the success of their lead asset, apitegromab, which has demonstrated statistically significant and clinically meaningful improvements in motor function for patients with spinal muscular atrophy (SMA) using the Hammersmith Motor Function Scale. Looking ahead, Hallal expressed excitement about the next 12 to 18 months, during which the company plans to file for regulatory approval based on these promising results. This marks a significant milestone for Scholar Rock as it continues to innovate in the treatment of SMA, a condition that has seen multiple failed attempts at intervention in the past two decades.
Advertisement
In-Article Ad
The advancements in myostatin biology and the potential approval of apitegromab could significantly improve treatment options for SMA patients, impacting their quality of life.
Advertisement
In-Article Ad
Reader Poll
What do you think about the advancements in myostatin biology?
Connecting to poll...
Read the original article
Visit the source for the complete story.